August 11, 2020 – The Baylor Scott & White Research Institute last Wednesday enrolled the first patient in the world for the ACTIV-3 clinical trial just one day after the initiative was launched by the National Institutes of Health (NIH). A second patient was enrolled the following day.
The NIH ACTIV-3 Trial is part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program created in a partnership between the National Institute of Allergy and Infectious Diseases (NIAID) and the National Heart, Lung, and Blood Institute (NHLBI). The two institutes within the NIH collaborated to combine their clinical trial networks and create a worldwide network of 400 sites to evaluate promising therapies in an adaptive trial design platform. The ACTIV-3 Trial will test the safety and effectiveness of a potential new treatment option, a neutralizing monoclonal antibody manufactured by Eli Lilly and Company for hospitalized patients with COVID-19.
ACTIV-3 marks the latest trial of nearly two dozen COVID-19-related research trials offered by Baylor Scott & White Research Institute.
Patients who are hospitalized with confirmed cases of COVID-19 may volunteer for participation in the study. The ACTIV-3 study will begin by studying the investigational monoclonal antibody LY-CoV555, which was identified in a blood sample from a recovered COVID-19 patient. Participants also will receive standard care for COVID-19, including the antiviral remdesivir.
The ACTIV-3 trial will only take place at 400 select hospitals worldwide that are part of NIAID and NHLBI clinical trial networks.
